{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Investigator%27s+Choice+of+Chemotherapy&page=6", "query": { "intervention": "Investigator's Choice of Chemotherapy", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 147, "total_pages": 15, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Investigator%27s+Choice+of+Chemotherapy&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Investigator%27s+Choice+of+Chemotherapy&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T04:55:17.559Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02625623", "title": "Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma", "Gastric Cancer Third Line" ], "interventions": [ { "name": "Avelumab", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Best Supportive Care (BSC)", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 371, "start_date": "2015-12-28", "completion_date": "2019-11-13", "has_results": true, "last_update_posted_date": "2020-11-24", "last_synced_at": "2026-10-14T04:55:17.559Z", "location_count": 28, "location_summary": "Denver, Colorado • Pueblo, Colorado • Miami, Florida + 24 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Pueblo", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Ocala", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02625623" }, { "nct_id": "NCT03493854", "title": "A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Early Breast Cancer" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pertuzumab IV", "type": "DRUG" }, { "name": "FDC of Pertuzumab and Trastuzumab SC", "type": "DRUG" }, { "name": "Trastuzumab IV", "type": "DRUG" }, { "name": "Trastuzumab SC", "type": "DRUG" }, { "name": "Surgery", "type": "PROCEDURE" }, { "name": "Post-operative Radiotherapy", "type": "RADIATION" }, { "name": "Hormone Therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 500, "start_date": "2018-06-14", "completion_date": "2023-06-02", "has_results": true, "last_update_posted_date": "2024-06-26", "last_synced_at": "2026-10-14T04:55:17.559Z", "location_count": 4, "location_summary": "Rockville, Maryland • Farmington, New Mexico • Charlotte, North Carolina + 1 more", "locations": [ { "city": "Rockville", "state": "Maryland" }, { "city": "Farmington", "state": "New Mexico" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Lakewood", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03493854" }, { "nct_id": "NCT03066778", "title": "A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Small Cell Lung Cancer (SCLC)" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Normal saline solution", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 453, "start_date": "2017-05-02", "completion_date": "2021-09-21", "has_results": true, "last_update_posted_date": "2022-10-03", "last_synced_at": "2026-10-14T04:55:17.559Z", "location_count": 27, "location_summary": "Miami, Florida • Chicago, Illinois • Evanston, Illinois + 21 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Evanston", "state": "Illinois" }, { "city": "Munster", "state": "Indiana" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03066778" }, { "nct_id": "NCT02951156", "title": "Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Avelumab", "type": "BIOLOGICAL" }, { "name": "Utomilumab", "type": "BIOLOGICAL" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Azacitidine", "type": "OTHER" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2016-12-16", "completion_date": "2019-12-02", "has_results": true, "last_update_posted_date": "2020-12-17", "last_synced_at": "2026-10-14T04:55:17.559Z", "location_count": 9, "location_summary": "Duarte, California • Louisville, Kentucky • New Orleans, Louisiana + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02951156" }, { "nct_id": "NCT04949256", "title": "Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Esophageal Squamous Cell Carcinoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Levoleucovorin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 863, "start_date": "2021-07-28", "completion_date": "2026-05-20", "has_results": true, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-10-14T04:55:17.559Z", "location_count": 15, "location_summary": "Duarte, California • Washington D.C., District of Columbia • Louisville, Kentucky + 10 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04949256" }, { "nct_id": "NCT06901531", "title": "A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer", "Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer", "Metastatic Gastric Adenocarcinoma or Cancer", "Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma" ], "interventions": [ { "name": "zolbetuximab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Folinic acid (leucovorin or local equivalent)", "type": "DRUG" }, { "name": "5-fluorouracil (5-FU)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 500, "start_date": "2025-05-22", "completion_date": "2028-09-30", "has_results": false, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-10-14T04:55:17.559Z", "location_count": 37, "location_summary": "Birmingham, Alabama • Bakersfield, California • Cerritos, California + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Bakersfield", "state": "California" }, { "city": "Cerritos", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06901531" }, { "nct_id": "NCT05032352", "title": "Predictive Assay for Decision Making in Adjuvant Therapy", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Adjuvant", "type": "DRUG" }, { "name": "Observation", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Insight Molecular Diagnostics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2022-01-28", "completion_date": "2022-10-28", "has_results": false, "last_update_posted_date": "2022-11-14", "last_synced_at": "2026-10-14T04:55:17.559Z", "location_count": 18, "location_summary": "Duarte, California • Washington D.C., District of Columbia • Jupiter, Florida + 13 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jupiter", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05032352" }, { "nct_id": "NCT05048797", "title": "A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Locally Advanced or Metastatic Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Trastuzumab Deruxtecan", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "123 Years", "sex": "ALL", "summary": "18 Years to 123 Years" }, "enrollment_count": 454, "start_date": "2021-10-28", "completion_date": "2027-07-30", "has_results": false, "last_update_posted_date": "2026-07-10", "last_synced_at": "2026-10-14T04:55:17.559Z", "location_count": 19, "location_summary": "Anchorage, Alaska • Los Alamitos, California • Los Angeles, California + 16 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05048797" }, { "nct_id": "NCT05635708", "title": "A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer", "Metastatic Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Tislelizumab", "type": "DRUG" }, { "name": "BGB-A445", "type": "DRUG" }, { "name": "LBL-007", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "pemetrexed", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab paclitaxel", "type": "DRUG" }, { "name": "BGB-15025", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 400, "start_date": "2023-03-07", "completion_date": "2026-10", "has_results": false, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-10-14T04:55:17.559Z", "location_count": 5, "location_summary": "Los Angeles, California • Boston, Massachusetts • New York, New York + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Portland", "state": "Oregon" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05635708" }, { "nct_id": "NCT03610724", "title": "Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Tisagenlecleucel", "type": "BIOLOGICAL" }, { "name": "lymphodepleting chemotherapy", "type": "DRUG" }, { "name": "Bridging Therapy", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "25 Years", "sex": "ALL", "summary": "Up to 25 Years" }, "enrollment_count": 34, "start_date": "2019-02-15", "completion_date": "2023-04-26", "has_results": true, "last_update_posted_date": "2024-06-20", "last_synced_at": "2026-10-14T04:55:17.559Z", "location_count": 8, "location_summary": "Los Angeles, California • San Francisco, California • Baltimore, Maryland + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03610724" } ] }